PWMG
ACAD icon

Prestige Wealth Management Group’s Acadia Pharmaceuticals ACAD Stock Holding History

Prestige Wealth Management Group’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-100
Closed -$2K – 1148
2022
Q3 		$2K Hold
100
– – ﹤0.01% 704
2022
Q2 		$1K Hold
100
– – ﹤0.01% 814
2022
Q1 		$2K Hold
100
– – ﹤0.01% 746
2021
Q4 		$2K Hold
100
– – ﹤0.01% 766
2021
Q3 		$2K Hold
100
– – ﹤0.01% 772
2021
Q2 		$2K Hold
100
– – ﹤0.01% 764
2021
Q1 		$3K Hold
100
– – ﹤0.01% 703
2020
Q4 		$5K Buy
+100
New +$4.96K ﹤0.01% 561

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Prestige Wealth Management Group's ACAD Position: Q4 2022 in Review

Prestige Wealth Management Group sold out of Acadia Pharmaceuticals (ACAD) in Q4 2022, closing a stake of 100 shares — an estimated $2K sold.

Prestige Wealth Management Group first reported a position in ACAD in Q4 2020 and held it in 8 quarters. The position peaked at $5K in Q4 2020. 227 funds tracked by Wall St. Rank hold ACAD as of Q4 2022.

  • Prestige Wealth Management Group reported no remaining Acadia Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Prestige Wealth Management Group sold 100 Acadia Pharmaceuticals shares in Q4 2022, an estimated $2K.
  • Prestige Wealth Management Group first reported a position in Acadia Pharmaceuticals in Q4 2020 and held it in 8 quarters.
  • Prestige Wealth Management Group's Acadia Pharmaceuticals position peaked at $5K in Q4 2020.
  • 227 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2022.

Based on Prestige Wealth Management Group's 13F filing for Q4 2022, filed 8 Feb 2023.